NCT04335552View on ClinicalTrials.gov

Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 17, 2020

Primary Completion Date

June 17, 2020

Study Completion Date

June 26, 2020

Conditions
SARS-CoV-2
Interventions
OTHER

Standard of care

Standard of care

DRUG

Hydroxychloroquine

Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5

DRUG

Azithromycin

Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5

Trial Locations (4)

27609

Duke Raleigh Hospital, Raleigh

27704

Duke Regional Hospital, Durham

27710

Duke University Hospital, Durham

Durham VA Medical Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER

NCT04335552 - Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection | Biotech Hunter | Biotech Hunter